Fig. 4
From: Metformin reverses mesenchymal phenotype of primary breast cancer cells through STAT3/NF-κB pathways
Metformin reverses IL-6-induced EMT in primary epithelial breast cancer cells by inhibiting STAT3 and NF-κB phosphorylation. MBCDF and MBCD17 cells were treated with 40 ng/mL IL-6. At day 1, MTF was added to cells incubated in the presence or absence of IL-6. After 2 days of incubation all conditions were collected for protein extraction and Western blot analysis. a Effect of MTF on IL-6-induced EMT markers (E-cadherin, Vimentin, and SNAIL). b Effect of MTF on IL-6-induced activation of STAT3 was assessed as in Fig. 3b. c Effect of MTF on IL-6-induced NF-κB phosphorylation was assessed as in Fig. 3c. Actin was used as loading control